Efficacy and safety of OATD-01, an oral inhibitor of chitinase-1, for treatment of active pulmonary sarcoidosis: study protocol for a randomized, double-blind, placebo- controlled, multicenter, phase 2 trial.EUROPEAN RESPIRATORY JOURNALIF212024-10-300PRE
Multicenter, randomized, double-blind, phase 2 study to assess the efficacy and safety of OATD-01, an oral inhibitor of chitinase-1 for the treatment of active pulmonary sarcoidosis.EUROPEAN RESPIRATORY JOURNALIF212023-10-270PRE
The Role of Chitinases in Chronic Airway Inflammation Associated with Tobacco Smoke ExposureCELLSIF5.22022-11-253OAAI
Pharmacological Inhibition of Chitotriosidase (CHIT1) as a Novel Therapeutic Approach for Sarcoidosisinflammation researchIF4.12022-09-017OA
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I-Indole DerivativesPHARMACEUTICALSIF4.82022-07-303OAAI
Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosisEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72022-03-0111OAAI
Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary FibrosisJOURNAL OF MEDICINAL CHEMISTRYIF6.82020-10-2016PREAI
Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian ChitinaseACS MEDICINAL CHEMISTRY LETTERSIF42020-04-2410OA
Discovery and Pharmacokinetics of Sulfamides and Guanidines as Potent Human Arginase 1 InhibitorsACS MEDICINAL CHEMISTRY LETTERSIF42020-03-1329OAAI
Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System DiseasesJOURNAL OF MEDICINAL CHEMISTRYIF6.82019-07-1019PREAI
CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosisEUROPEAN RESPIRATORY JOURNALIF212018-11-197PRE
Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseasesEUROPEAN RESPIRATORY JOURNALIF212018-11-191PRE
Targeting Acidic Mammalian chitinase Is Effective in Animal Model of AsthmaJOURNAL OF MEDICINAL CHEMISTRYIF6.82018-01-1123PREAI
The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in miceEUROPEAN RESPIRATORY JOURNALIF212017-12-061PRE
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitorsEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72015-10-017PREAI
Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cellsGASTRIC CANCERIF5.12014-11-1963OAAI
Discovery of CPL-407-22-Novel, Potent and Highly Selective JAK2 Kinase InhibitorEUROPEAN JOURNAL OF CANCERIF7.12012-11-010PREAI
Differential Gene Expression Profile in Response to the Treatment With JAK2 Inhibitors - Ruxolitinib, SAR302503 and LY2784544EUROPEAN JOURNAL OF CANCERIF7.12012-07-010OAAI
NPM-ALK I1171T Mutation Confers Resistance to Crizotinib in Anaplastic Large Cell LymphomaEUROPEAN JOURNAL OF CANCERIF7.12012-07-010PREAI